This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, L. Articles by Tsuruo, T. Search for Related Content PubMed PubMed Citation Articles by Yang, L. Articles by Tsuruo, T.

Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells

Therapeutic Effect of a Novel Polyarginine-conjugated Smac Peptide¹

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 170-8455 [L. Y., T. M., S. S., M. M., H. S., T. Y., T. O-h., T. T.], and Institute of Molecular and Cellular Biosciences, the University of Tokyo, Tokyo 113-0032 [L. Y., H. S., T. T.], Japan

The inhibitor of apoptosis proteins (IAPs) plays a central role in repressing caspase-mediated cell death. However, little is known about the actual role of endogenously expressed IAPs in cancer cells. We found that the cytochrome c/apoptotic protease-activating factor-1 (apoptosome)-dependent caspase activation is deficient in human non-small cell lung cancer (NSCLC) NCI-H460 cells. This dysfunctional apoptosome activity was not correlated with any decrease of apoptosome component factors, but it was linked to an increased X-linked inhibitor of apoptosis protein (XIAP). In H460 cells, the overexpressed XIAP, but not c-IAP1, bound to the processed form of caspase-9 and suppressed the activation of downstream effector caspases. Moreover, the defect in apoptosome activity in H460 cells was dramatically restored by the IAP-targeting SmacN7 peptide, which disrupted XIAP-caspase-9 binding, indicating an essential role of the IAP in the apoptosome inhibition. However, the SmacN7 did not show any striking effect on the apoptosome activity of normal lung fibroblast cells, although these cells also expressed modest amounts of IAP. To explore the therapeutic approach, we additionally developed SmacN7(R)8, a newly designed cell permeable peptide. The SmacN7(R)8 selectively reversed the apoptosis resistance of H460 cells, and when in combination with chemotherapy, regressed the tumor growth in vivo with little toxicity to the mice. Our results indicate that IAP-dependent suppression of apoptosome predominantly occurs in IAP-overexpressing tumor, and the IAP-targeting Smac peptide is an effective molecule to increase tumor cell death induced by chemotherapy in vitro and in vivo.

This article has been cited by other articles:

				S Ghavami, M Hashemi, S R Ande, B Yeganeh, W Xiao, M Eshraghi, C J Bus, K Kadkhoda, E Wiechec, A J Halayko, et al. Apoptosis and cancer: mutations within caspase genes J. Med. Genet., August 1, 2009; 46(8): 497 - 510. [Abstract] [Full Text] [PDF]

				A. El-Sayed, I. A. Khalil, K. Kogure, S. Futaki, and H. Harashima Octaarginine- and Octalysine-modified Nanoparticles Have Different Modes of Endosomal Escape J. Biol. Chem., August 22, 2008; 283(34): 23450 - 23461. [Abstract] [Full Text] [PDF]

				M. J. Tang and I. T. Tai A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers J. Biol. Chem., November 23, 2007; 282(47): 34457 - 34467. [Abstract] [Full Text] [PDF]

				D. Vucic and W. J. Fairbrother The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer Clin. Cancer Res., October 15, 2007; 13(20): 5995 - 6000. [Abstract] [Full Text] [PDF]

				J. Voortman, A. Checinska, G. Giaccone, J. A. Rodriguez, and F. A.E. Kruyt Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460 Mol. Cancer Ther., March 1, 2007; 6(3): 1046 - 1053. [Abstract] [Full Text] [PDF]

				D. Chauhan, P. Neri, M. Velankar, K. Podar, T. Hideshima, M. Fulciniti, P. Tassone, N. Raje, C. Mitsiades, N. Mitsiades, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) Blood, February 1, 2007; 109(3): 1220 - 1227. [Abstract] [Full Text] [PDF]

				Z. T. Schafer, A. B. Parrish, K. M. Wright, S. S. Margolis, J. R. Marks, M. Deshmukh, and S. Kornbluth Enhanced Sensitivity to Cytochrome c-Induced Apoptosis Mediated by PHAPI in Breast Cancer Cells Cancer Res., February 15, 2006; 66(4): 2210 - 2218. [Abstract] [Full Text] [PDF]

				S. Giagkousiklidis, M. Vogler, M.-A. Westhoff, H. Kasperczyk, K.-M. Debatin, and S. Fulda Sensitization for {gamma}-Irradiation-Induced Apoptosis by Second Mitochondria-Derived Activator of Caspase Cancer Res., November 15, 2005; 65(22): 10502 - 10513. [Abstract] [Full Text] [PDF]

				U. Fischer and K. Schulze-Osthoff New Approaches and Therapeutics Targeting Apoptosis in Disease Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215. [Abstract] [Full Text] [PDF]

				T. Mashima, T. Oh-hara, S. Sato, M. Mochizuki, Y. Sugimoto, K. Yamazaki, J.-i. Hamada, M. Tada, T. Moriuchi, Y. Ishikawa, et al. p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target J Natl Cancer Inst, May 18, 2005; 97(10): 765 - 777. [Abstract] [Full Text] [PDF]

				B. Z. Carter, M. Gronda, Z. Wang, K. Welsh, C. Pinilla, M. Andreeff, W. D. Schober, A. Nefzi, G. R. Pond, I. A. Mawji, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells Blood, May 15, 2005; 105(10): 4043 - 4050. [Abstract] [Full Text] [PDF]

				D. A. Fennell Caspase Regulation in Non-Small Cell Lung Cancer and its Potential for Therapeutic Exploitation Clin. Cancer Res., March 15, 2005; 11(6): 2097 - 2105. [Abstract] [Full Text] [PDF]

				A. D. Schimmer and S. Dalili Targeting the IAP Family of Caspase Inhibitors as an Emerging Therapeutic Strategy Hematology, January 1, 2005; 2005(1): 215 - 219. [Abstract] [Full Text] [PDF]

				A. D. Schimmer Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice Cancer Res., October 15, 2004; 64(20): 7183 - 7190. [Abstract] [Full Text] [PDF]

				L. Li, R. M. Thomas, H. Suzuki, J. K. De Brabander, X. Wang, and P. G. Harran A Small Molecule Smac Mimic Potentiates TRAIL- and TNF{alpha}-Mediated Cell Death Science, September 3, 2004; 305(5689): 1471 - 1474. [Abstract] [Full Text] [PDF]

				Q.-H. Yang and C. Du Smac/DIABLO Selectively Reduces the Levels of c-IAP1 and c-IAP2 but Not That of XIAP and Livin in HeLa Cells J. Biol. Chem., April 23, 2004; 279(17): 16963 - 16970. [Abstract] [Full Text] [PDF]

				M. Krajewska, S. Krajewski, S. Banares, X. Huang, B. Turner, L. Bubendorf, O.-P. Kallioniemi, A. Shabaik, A. Vitiello, D. Peehl, et al. Elevated Expression of Inhibitor of Apoptosis Proteins in Prostate Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4914 - 4925. [Abstract] [Full Text] [PDF]

				F. A. E. Kruyt, A. Checinska, G. Giaccone, and C. G. Ferreira Correspondence re: L. Yang et al., Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells: Therapeutic Effect of a Novel Polyarginine-conjugated Smac Peptide. Cancer Res., 63: 831-837, 2003. Cancer Res., October 1, 2003; 63(19): 6566 - 6567. [Full Text] [PDF]

				X. Hong, L. Lei, and R. Glas Tumors Acquire Inhibitor of Apoptosis Protein (IAP)-mediated Apoptosis Resistance through Altered Specificity of Cytosolic Proteolysis J. Exp. Med., June 16, 2003; 197(12): 1731 - 1743. [Abstract] [Full Text] [PDF]